Last update Feb. 12, 2019


Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

A tertiary antimuscarinic amine with actions similar to atropine. Indicated as a urinary antispasmodic in bladder incontinence problems.
Oral administration 1 to 3 times a day.

Since the last update we have not found published data on its excretion in breastmilk.

Its pharmacokinetic data - large volume of distribution and high percentage of protein binding (AEMPS2016, Ortho2008) - make it unlikely that significant quantities will be transferred to breastmilk.

Its very low oral bioavailability (AEMPS2016, Ortho2008, Duchamos 1988) hinders transfer to infant plasma from breastmilk, except in premature infants and the immediate neonatal period when there may be greater intestinal permeability.

Milk production should be monitored, since anticholinergics can reduce milk production.

Possible anticholinergic symptoms (dry mouth, constipation...) in the infant should be monitored.

Expert authors consider the use of this medication to probably be safe during breastfeeding (Brigs 2017, Hale 2017 p 737).
Other similar anticholinergics, such as atropine, are considered by the American Academy of Pediatrics to usually be compatible with breastfeeding.

See below the information of this related product:

  • Atropine (Safe substance and/or breastfeeding is the best option.)


  • Tamsulosin (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

G04BD04 is Oxybutynin in ATC Code/s.

Is written in other languages:

G04BD04 is also known as


Variable Value Unit
Oral Bioavail. 6 (2 - 11) %
Molecular weight 358 daltons
Protein Binding 91 - 93 %
VD 2.76 l/Kg
pKa 8.77 -
Tmax 1 hours
2 - 4 hours


  1. Hale TW, Rowe HE. Medications & Mothers' Milk. A Manual of Lactation Pharmacology. Springer Publishing Company. 2017
  2. AEMPS-Sanofi. Oxibutinina. Ficha técnica. 2016 Full text (in our servers)
  3. Briggs GG, Freeman RK, Towers CV, Forinash AB. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Wolters Kluwer Health. Tenth edition (acces on line) 2015
  4. Ortho. Oxybutynin. Drug Summary. 2008 Full text (in our servers)
  5. Douchamps J, Derenne F, Stockis A, Gangji D, Juvent M, Herchuelz A. The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol. 1988 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM